Liquidia (NASDAQ:LQDA) Director Sells $4,669,738.92 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 72,534 shares of Liquidia stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $64.38, for a total value of $4,669,738.92. Following the sale, the director directly owned 1,564,407 shares in the company, valued at approximately $100,716,522.66. This trade represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liquidia Stock Performance

LQDA stock traded up $1.24 during trading on Wednesday, reaching $65.25. 2,327,936 shares of the stock were exchanged, compared to its average volume of 1,722,392. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The stock has a 50 day simple moving average of $47.90 and a 200-day simple moving average of $40.11. The company has a market capitalization of $5.80 billion, a P/E ratio of 466.10 and a beta of 0.58. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $66.78.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s revenue was up 4187.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current year.

Institutional Trading of Liquidia

Large investors have recently made changes to their positions in the company. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter valued at $37,114,000. Apis Capital Advisors LLC acquired a new position in shares of Liquidia during the 3rd quarter worth about $9,569,000. Farallon Capital Management LLC boosted its stake in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after buying an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of Liquidia by 63.6% during the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after buying an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Liquidia during the 3rd quarter worth about $1,536,000. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

LQDA has been the subject of several research analyst reports. HC Wainwright boosted their price objective on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Raymond James Financial restated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.63.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).